secwatch.observer — SEC 8-K summary
======================================

Issuer:     MAXCYTE, INC. (MXCT)
CIK:        0001287098
Form:       8-K
Filed at:   2026-03-24T23:59:59+00:00
Accession:  0001104659-26-033867
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

MaxCyte Q4 revenue $7.3M, down 16%; FY2025 revenue $33M; guides FY2026 $30-32M
------------------------------------------------------------------------------

- Q4 2025 total revenue $7.3M (-16% YoY); Core revenue $6.8M (-22% YoY). Net loss $9.6M.
- FY2025 total revenue $33.0M (-15% YoY); Core revenue $29.6M (-9% YoY). Net loss $44.6M.
- Cash and investments $155.6M at Dec 31, 2025, vs $190.3M a year earlier.
- FY2026 guidance: total revenue $30-32M ($25-27M core, $5M SPL); expects cash ≥$136M.
- Ended 2025 with 32 SPLs, 13 clinical programs in clinic, and one commercial program.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1287098/000110465926033867/0001104659-26-033867-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1287098/000110465926033867/mxct-20260324x8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-033867

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer